RenovoRx (RNXT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
The annual meeting is scheduled for June 30, 2026, with shareholders of record as of May 11, 2026, eligible to vote on key proposals.
The Board unanimously recommends voting in favor of all proposals, including director elections, an equity plan amendment, and auditor ratification.
Proxy materials are available online and by mail, and shareholders can vote via internet, mail, or in person.
Voting matters and shareholder proposals
Shareholders will vote to elect six directors, approve an amendment to the 2021 Omnibus Equity Incentive Plan to add 2,000,000 shares, and ratify the appointment of Frank Rimerman + Co. LLP as the independent auditor for 2026.
The Board recommends a vote "FOR" all proposals.
Shareholders may submit proposals or director nominations for the 2027 meeting by specified deadlines.
Board of directors and corporate governance
The Board consists of six members, four of whom are independent under Nasdaq rules.
Committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined responsibilities and independent chairs.
The Board separates the roles of CEO and Executive Chairman and regularly holds executive sessions of independent directors.
Director candidates are evaluated based on independence, diversity, expertise, and commitment to shareholder interests.
Latest events from RenovoRx
- Record Q2 2026 revenue, raised guidance, and expansion beyond core market signal strong growth.RNXT
Q2 2026 - Strong commercial growth and clinical data position the therapy for major impact in cancer care.RNXT
IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 - TAMP platform and RenovoCath device drive clinical and commercial momentum in targeted oncology.RNXT
Investor presentation - Targeted chemo delivery platform drives revenue growth and nears key clinical milestones.RNXT
A.G.P.'s Annual Virtual Healthcare Conference - Record Q1 revenue and expanding cancer center adoption drive growth, but losses and Nasdaq risks persist.RNXT
Q1 2026 - RenovoCath's targeted delivery platform drives adoption, revenue growth, and promising clinical results.RNXT
Investor presentation - Registers resale of 15.96M shares after $10M private placement; growth in device adoption and revenue.RNXT
Registration filing - Revenue grows to $900,000 YTD as RenovoCath adoption expands and clinical programs advance.RNXT
Q3 2025 - Q1 2025 RenovoCath sales hit ~$200,000, surpassing expectations but losses and risks remain.RNXT
Q1 2025